Markedly elevated CA19-9 associated with benign ovarian cyst and ascites
暂无分享,去创建一个
[1] M. Santis,et al. Tumour markers in internal medicine: a low-cost test or an unnecessary expense? A retrospective study based on appropriateness , 2007, Internal and emergency medicine.
[2] Shakir Ali,et al. Increased serum carcinomic antigen 19-9(CA 19-9) in a dermoid cyst , 2007, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.
[3] V. Heinemann,et al. Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer , 2006, Oncology.
[4] C. Atabekoğlu,et al. Elevated carbohydrate antigen 19‐9 in a dermoid cyst , 2005, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[5] S. Loi,et al. Towards evidence‐based use of serum tumour marker requests: an audit of use in a tertiary hospital , 2004, Internal medicine journal.
[6] A. Sevinç,et al. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology. , 2001, Hepato-Gastroenterology.
[7] Shou-Dong Lee,et al. Clinical value of tumour markers and serum‐ascites albumin gradient in the diagnosis of malignancy‐related ascites , 1994, Journal of gastroenterology and hepatology.
[8] M. Herlyn,et al. Specific antigen in serum of patients with colon carcinoma. , 1981, Science.
[9] K. Takahashi,et al. Abnormally high values of CA 125 and CA 19-9 in women with benign tumors. , 1989, Gynecologic and obstetric investigation.